Results 161 to 170 of about 3,685,138 (295)

Therapy-educated fibroblast states link treatment pressure to residual disease and acquired resistance in gastric cancer. [PDF]

Front Immunol
Chen Z, Yang Y, Yang T, Gao L, Zhou T, Deng M.   +5 more
europepmc   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy. [PDF]

J Gastrointest Oncol
Pathak P, Caughey B, Barnes H, Strickland M, Walsh E, Clark J, Blazkowsky L, Parikh A, Weekes C, Klempner S, Corcoran R.   +10 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Liposomal-Mitoxantrone Overcomes Acquired Resistance and Enhances Venetoclax Synergy in AML-Mechanistic Insights and Preliminary Clinical Evidence. [PDF]

Int J Nanomedicine
Luo K, Hui Y, Shen H, Yan L, Zeng Y, Zhou L, Wang M, Wang J, Liu M, Wei H.   +9 more
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. [PDF]

EMBO Mol Med
Buzo K, Bizzozero L, Lentini M, Opattova A, Hernández-Suárez B, Torres M, Chiabotto G, Nisticò C, De Lazzari G, R Zanella E, Grasso G, Mariella E, Durinikova E, Linnebacher M, Sartore-Bianchi A, Siena S, Trusolino L, Bardelli A, Arena S.   +18 more
europepmc   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. [PDF]

Nat Med
Aronchik I, Kar S, Zhuang Y, Ahler E, Lai LP, Seshadri V, Yang YC, Bulle A, Menard M, Nayak B, Labrecque MP, Dilly J, Kim E, Jiang L, Yano J, Wasko UN, Helland C, Bredeson S, Garrick B, Gindin Y, Sickler B, Wei X, Seamon K, Jiang J, Lim KH, Holderfield M, Quintana E, Hegde A, Salman Z, Starodub A, Spira A, Park W, Hong DS, Barve M, Pelster M, Sommerhalder D, Punekar SR, Garrido-Laguna I, Wolpin BM, Maitra A, Gustafson WC, Kelsey S, Smith JAM, Lin KK, Aguirre AJ, Singh M.   +45 more
europepmc   +1 more source

Arginine methylation as a regulatory ratchet in cancer: From substrate selection to malignant‐state stabilization

Molecular Oncology, EarlyView.
Arginine methylation can be viewed as a persistence‐prone post‐translational modification regulated by a network of PRMTs. Competitive and compensatory interactions among PRMTs can redistribute methylation across substrate pools shaped by sequence, structural, spatial, and environmental layers, reinforcing RNA‐processing, chromatin, and signaling ...
So Hyun Kwon, Ji Min Lee
wiley   +1 more source